Telix Pharmaceuticals Limited

TLX

AU000000TLX2

Biotechnology & Medical Research

Delayed Australian S.E. Other stock markets 01:12:36 19/06/25 pm AEST			5-day change	1st Jan Change
25.24 ^AUD	-1.98%		-1.52%	+2.64%

13/06	Telix Pharmaceuticals Limited Announces Prostate Cancer PSMA-PET Imaging Agent Approved in Greece	CI
12/06	Telix Pharmaceuticals Limited - Analyst/Investor Day

Wedbush Initiates Telix Pharmaceuticals at Outperform With $22 Price Target

Published on 05/06/2025 at 20:56

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Telix Pharmaceuticals Limited

Telix Pharmaceuticals Limited Announces Prostate Cancer PSMA-PET Imaging Agent Approved in Greece	13/06	CI
Telix Pharmaceuticals Limited - Analyst/Investor Day	12/06
Telix Pharmaceuticals Announces Gozellix Now Available Nationally In U.S.	12/06	RE
Telix Launches New Prostate Cancer Imaging Agent, Gozellix, in U.S	11/06	CI
Telix Opens Manufacturing Facility in Japan	06/06	MT
Wedbush Initiates Telix Pharmaceuticals at Outperform With $22 Price Target	05/06	MT
Eckert & Ziegler Has Entered into A Distribution Agreement with Telix Pharmaceuticals Limited for the Prostate Cancer Pet Imaging Agent, Illuccix®, in Germany	05/06	CI
Telix Pharmaceuticals Limited's Illuccix® PSMA-PET Imaging Agent Approves in Portugal	04/06	CI
Telix Says Publication of Thyroid Cancer Therapy Candidate in American Thyroid Association Journal Validates Safety Profile	08/05	MT
Telix Pharmaceuticals Limited's Illuccix PSMA-PET Imaging Agent Approved in the Czech Republic	05/05	CI
Illuccix Prostate Cancer Psma-Pet Imaging Agent Approved In Finland	30/04	RE
Telix Pharmaceuticals Limited Announces Illuccix Prostate Cancer PSMA-PET Imaging Agent Approve in Finland	30/04	CI
Telix Pharmaceuticals Secures Marketing Authorization for Prostate Cancer Imaging Agent in France	29/04	MT
Telix Pharmaceuticals Limited Announces Resignation of Anne Whitaker from its Board, Effective 29 April 2025	29/04	CI
Telix Pharmaceuticals Says FDA Requires Additional Clinical Evidence For Tlx101-Cdx Approval	28/04	RE
Telix Pharmaceuticals Says US FDA Ruled New Drug Application for Brain Cancer Imaging Agent 'Cannot be Approved in Current Form'; Shares Down 7%	28/04	MT
Telix Pharmaceuticals Limited - Special Call	28/04
Telix Pharmaceuticals Limited Receives Complete Response Letter from United States Food and Drug Administration for its New Drug Application for TLX101-CDx	28/04	CI
Telix Pharmaceuticals' Revenue Soars 62% in Q1; Fiscal 2025 Guidance Reaffirmed	23/04	MT
ASX Preview: Australian Shares to Open Higher After Wall Street Advances on Trade Hopes	23/04	MT
Sector Update: Health Care Stocks Rise Pre-Bell Tuesday	22/04	MT
Telix Pharmaceuticals Q1 Revenue Increases; 2025 Revenue Outlook Reaffirmed	22/04	MT
Telix Pharmaceuticals Limited Reaffirms Earnings Guidance for the Fiscal Year 2025	22/04	CI
Telix Pharmaceuticals Posts Q1 2025 Unaudited Revenue Of $186 Million	22/04	RE
Telix Pharmaceuticals Limited Reports Unaudited Revenue Results for the First Quarter of 2025	22/04	CI

Chart Telix Pharmaceuticals Limited

Duration

Period

TLX: Dynamic Chart

Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical devices. It develops a portfolio of clinical and commercial stage products that addresses significant unmet medical needs in oncology and rare diseases. It operates a pipeline of theranostic radiopharmaceutical product candidates with a focus on urologic oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma) and bone marrow conditioning. Its segments include commercial, product development, medical technologies, and manufacturing services. Its lead imaging product is gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix). Its other pipelines include TLX591, TLX592, TLX250, TLX101, TLX300, TLX66, TLX66-CDx, and TLX090, among others.

Employees

423

Sector

Biotechnology & Medical Research

Calendar

21/08 - Q2 2025 Earnings Release (Projected)

More about the company